Summit Therapeutics is in the drug manufacturers industry and healthcare sector. Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Previous Intraday Performance:

The SMMT shares had a previous change of -2.31% which opened at 1.73 and closed at 1.73. It moved to an intraday high of 1.72 and a low of 1.69.

SeekingAlpha:  Summit Therapeutics reports data for DDS-04 for Enterobacteriaceae at ECCMID 2019

Historical Performance:

Over the last five trading days, SMMT shares returned -2.26% and in the past 30 trading days it returned -5.46%. Over three months, it changed 33.08%. In one year it has changed -87.63% and within that year its 52-week high was 14.20 and its 52-week low was 1.10. SMMT stock is 57.27% above its 52 Week Low.

Our calculations result in a 200 day moving average of 1.78 and a 50 day moving average of 1.87. Right now, SMMT stock is trading -3.08% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.

SeekingAlpha:  Summit Therapeutics reports data for DDS-04 for Enterobacteriaceae at ECCMID 2019


The company has a market cap of $54.2m with 32.1m shares outstanding and a float of 32.1m shares. Trading volume was 1,210 shares and has experienced an average volume of 27,731 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Summit Therapeutics was 0.59 which ended on 31st of January 2019, which according to the previous close, that is a PE of 2.86. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.76.Historically, the PE high was 2.86 and the PE low was -2.11. SMMT stock has set a new PE low record!

Base on our calculations, the intrinsic value per share is 2.18, which means it might be undervalued and has a margin of safety of 20.82%

The next earnings report will be: 05-20-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Summit Therapeutics; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 164.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 8.40% of institutional ownership.

I calculated the beta to be 1.40

Business Wire:  SEACOR Marine Announces First Quarter 2019 Results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 38.25%, return on assets is 13.24%, profit margin is 34.14%, price-to-sales is 0.01 and price-to-book is 1.00.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 2  : Past Performance Result
 4  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here